Background/Aims: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor. This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune system is incompletely understood. Methods: The immune influence of cetuximab therapy in CRC patients was investigated by analyzing peripheral blood mononuclear cells using flow cytometry. We undertook in vitro cytotoxicity and cytokine-profile assays to ascertain the immunomodulatory effect of cetuximab treatment. Results: The number of CD3 + T, CD8 + T, and natural killer (NK) cells was increased significantly and T-regulatory cells reduced gradually after cetuximab treatment. Percentage of CD4 + T, natural killer T (NKT)-like, invariant NKT, and dendritic cells was similar between baseline patients and cetuximab patients. Expression of CD137 on NK and CD8 + T cells was increased significantly after 4 weeks of cetuximab therapy. In vitro cetuximab treatment markedly increased expression of CD137 and CD107a on NK and CD8 + T cells. Cetuximab treatment promoted the cytotoxic activity of NK and CD8 + T cells against tumor cells. Conclusion: Cetuximab treatment promotes activation of the immune response but alleviates immunosuppression: this might be the underlying anti-CRC effect of cetuximab.
Introduction
Colorectal cancer (CRC) carries a high mortality worldwide. Surgery is first-line treatment for CRC but up to 30-40% of patients relapse within the first few years after initial surgery [1] . Also, it has been reported that ≈60% CRC patients will go on to suffer from
Patients
The study protocol conformed to Declaration of Helsinki guidelines and was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University (Zhejiang, China) All individuals recruited in the study provided written informed consent. Written informed consent was obtained from all the enrolled participants. The study protocol was conducted with the approval of the Ethics Review Committee of the First Affiliated Hospital, Zhejiang University (Permit number: 2017-414), and the use of human blood samples was in accordance with the Guidelines of the Declaration of Helsinki.
Sixty-three (39 males and 24 females; 34-74 years) patients and 63 healthy controls (HCs: 36-70 years) were Table 1 .
Cell lines
The lines K562 (human leukemia cells) and HT-29 (colon carcinoma cells) were obtained from the Chinese Academy of Sciences (Beijing, China). Cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) containing 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% fetal calf serum (Integro, Zaandam, The Netherlands). Cells were passaged every 5 days and maintained in an incubator at 37°C in an atmosphere of 5% CO 2 .
Study design
Cetuximab (Erbitux ® , Merck, Darmstadt, Germany) was administered at 250 mg/m 2 body weight every week after a loading dose of 400 mg/m 2 . Patients were monitored for toxicity every week and laboratory tests were undertaken before each chemotherapy administration. Dose modification and/ or temporary or permanent discontinuation of any drug was at the discretion of the attending physician. Treatment was continued until radiological progression according to RECIST 1.0 criteria or unacceptable toxicity. Assessment with helical computed tomography (CT) was carried out within 28 days before the first cycle of therapy and then every 8-12 weeks. Confirmatory evaluation was not planned. We collected samples from CRC patients 2-4 weeks after the start of cetuximab treatment, Clinical, imaging, biochemical and immunologic parameters were assessed at baseline, 2 weeks and 4 weeks). Symptoms, tumor size, tumor marker index, and lymphocyte subsets were evaluated, and adverse events documented.
Flow cytometry
Several monoclonal antibodies were used in the present study. Fluorescein isothiocyanate (FITC)-anti-CD4, Phycoerythrin(PE)-anti-CD8, Pacific blue-anti-CD3, and Allophycocyanin（APC）-anti-CD25 were purchased from Beckman Coulter (Brea, CA, USA). APC-anti-CD127 was from eBioscience (San Diego, CA, USA). FITC-anti-CD56, PE-anti-CD19, PE-anti-BDCA1(CD1c), PE-anti-invariant natural killer T cells (iNKT), PE-anti-CD137, APC-anti-CD107, Phycoerythrin-Cy5 (PerCP-Cy5) -anti-CD137 and FITC-anti-CD8 were purchased from BD Biosciences (Franklin Lakes, NJ, USA). The cell surface marker phenotypes of each immune cell subset were listed in Table 2 . Data were acquired on a FACSCanto™ II flow cytometer (BD Biosciences) and analyzed with FlowJo (Treestar, Ashland, OR, USA) or BD FACS Diva (BD Biosciences) software. The description of the staining step has been described previously.
Isolation and culture of peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from samples collected at 0 (baseline), 2 weeks and 4 weeks after cetuximab therapy. Acquired PBMCs were cultured at 2×10 6 cells/mL in RPMI 1640 medium containing 10% fetal bovine serum (FBS), with stimulation with 5 mg/mL cetuximab or bovine serum albumin (BSA) for 24 hours. Cytotoxicity assay Isolated PBMCs were cultured overnight with recombinant human interleukin (IL)-2 (10 ng/mL). Target cells (HT-29; Chinese Academy of Sciences) were pre-labeled with carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes, Eugene, OA, USA) to differentiate them from PBMCs, as described previously [12] . PBMCs and HT-29 cells were harvested and seeded at an effector cell/target cell ratio of 10:1 for 12 h or 24 h. Cells were harvested and stained with 7-amino-actinomycin D (7-AAD, Calbiochem, eBioscience, San Diego, CA), the cytotoxic activity was assayed by flow cytometr.
Cytotoxicity assay using a real-time cell analyzer assay (RTCA)
To analyze cytotoxicity to CRC cells, a RTCA was undertaken using an xCELLigence™ RTCA system (E-plate 16; ACEA Biosciences, San Diego, CA, USA). This system consisted of a RTCA impedance analyzer, a SP station, 16-well E-Plates, and a personal computer with RTCA software to control operation of the system. For each RTCA, 50 μL of growth medium was added to each well for measurement of the impedance background. Then, 150 μL of RPMI 1640 medium supplemented with 10% FBS and containing 2000 cells was added to each well, and cell growth was assessed for ≈3-4 days.
HT-29 cells (5000 cells in 150 μL medium/ well) were seeded in 16-well plates in accordance with the xCELLigence RTCA instrument manual. PBMCs (250, 000 cells in 150 μL medium/well) (effector cell/target cell = 50:1) were added to the relevant wells. After 24 h, cetuximab (5 μM) was added and the experiment allowed to proceed for 3-4 days. An identical protocol was employed for NK cells and K562 cells.
Cytokine analyses
Cytokine levels in tissue homogenates and serum samples were assessed using an enzyme immunoassay according to manufacturer (Luminex, Austin, TX, USA) protocols.
Statistical analyses
Data were analyzed using Prism v6.0 (GraphPad, San Diego, CA, USA) and SPSS v19.0 (IBM, Armonk, NY, USA). Comparisons between the two groups were analyzed by the Student's t-test. Comparisons between several groups were analyzed by one-way ANOVA. Data are the mean ± SD and are representative of at least two independent experiments. P<0.05 was considered statistically significant.
Results

Cetuximab treatment changes the lymphocyte subset in the peripheral blood of CRC patients
To analyze the MoA of cetuximab during CRC treatment, we assessed the characteristics of lymphocytes in the peripheral blood of cetuximab-treated CRC patients. Compared with HCs, several lymphocyte subsets of peripheral blood were changed significantly. The number of CD3 + T cells, CD8 + T cells and NK cells was reduced significantly in baseline CRC patients compared with that in HCs (P=0.009, Fig. 1,) . However, the percentage of CD4 + T cells, natural killer T (NKT)-like cells, invariant natural killer T (iNKT) cells, and DCs in peripheral blood was similar between baseline CRC patients and HCs (Fig. 1C, Fig. 2 ). After 4 weeks of cetuximab treatment, the number of CD3 + T cells, CD8 + T cells and NK cells was increased significantly in cetuximab patients compared with baseline patients (Fig. 1A-B, D) . These findings suggested that cetuximab might enhance anti-tumor immunity. To determine the effect of cetuximab upon immunity, we analyzed the number of T regulatory (Treg) cells, which often have immunosuppressive roles in tumors. Cetuximab treatment reduced the percentage of Treg cells in CRC patients gradually (Fig. 2C) . Besides, the number of CD4 + T cells, NKT-like cells, iNKT cells and DCs in peripheral blood was not changed significantly after cetuximab treatment (P=0.34, Fig. 1C, 2A-B, D) . Collectively, these results suggested that the effect of CD3 
Cetuximab therapy induced CD137 expression on NK cells and CD8 + T cells in CRC patients
Recent studies have shown that CD137 is a member of the recently discovered tumor necrosis factor receptor (TNFR) superfamily. CD137 is involved in the NK cell-mediated effects of killing tumor cells [25] . Thus, we assessed the CD137 expression of NK cells in cetuximab-treated CRC patients.
Cetuximab treatment increased the CD137 expression on NK cells among CRC patients gradually (Fig. 3A) . Cetuximab treatment also increased the CD137 expression of CD8 + T cells in CRC patients (Fig. 3B) . There was no notable difference in CD137 expression on NKTlike and iNKT cells between HCs and baseline patients, and cetuximab treatment made no significant difference to the CD137 expression of NKT cells in CRC patients (Fig. 3C, D Fig. 5A, D) . Moreover, cetuximab treatment increased expression of CD137 and CD107a on NK cells and CD8 + T cells from the PBMCs of CRC patients significantly (Fig.4A-D , 5B-C, 5E-F). However, cetuximab treatment had no significant effect on expression of CD137 or CD107a on the NK cells and CD8 + T cells of HCs (Fig. 4A-D , 5B-C, 5E-F).
Cetuximab enhanced cytotoxicity against CRC cells
An in vitro experiment was designed and conducted to further investigate if cetuximab can enhance the toxicity of lymphocytes against CRC cells. Cetuximab treatment could significantly increase the cytotoxicity of HC-and CRC patient-derived PBMCs to HT-29 cells (Fig.6A, B) .
To confirm the role of NK cells in the cetuximab-enhanced cytotoxicity against tumor cells, RTCAs were used to carry out further experiments. Cetuximab treatment could enhance the cytotoxic effect of HC-and CRC patient-derived PBMCs on HT-29 cells (Fig. 6C) . RTCA data showed that cetuximab treatment could enhance the cytotoxic effect of HC-and CRC patient-derived NK cells on K562 cells (Fig. 6D) .
In summary, these data confirmed as it was previously demonstrated that cetuximab treatment could promote the cytotoxic activity of PBMCs and NK cells against tumor cells, which could be the underlying MoA of cetuximab against CRC cells [15] .
Cetuximab treatment affected the cytokine profile in plasma
To further study the enhanced effect of cetuximab on the immune response of CRC patients, plasma levels of IL-6, interferon (IFN)-γ and IL-10 were measured.
Cetuximab treatment could increase the IFN-γ level in the plasma of CRC patients gradually (Fig. 7B) . Levels of IL-6 and IL-10 were increased significantly in baseline patients 
Discussion
The impact of CRC has been a global health issue over the past decade [29, 30] . Studies have suggested that a high prevalence of mortality, recurrence and metastasis of CRC is associated with immunocompromised patients.
Cetuximab is a specific monoclonal antibody that can be used to inhibit the proliferation, invasion, and metastasis of tumor cells. Several studies have reported that cetuximab is effective in CRC treatment, but the underlying MoA is not known. Thus, we attempted to determine the anti-CRC MoA of cetuximab by analyzing the immunologic characteristics of CRC patients.
We found that the number of CD3 + T cells, CD8 + T cells and NK cells was increased significantly after cetuximab treatment in CRC patients. However, the percentage of CD4 + T cells, NKT-like cells, iNKT cells and DCs in peripheral blood was similar between baseline patients and HCs. CD137 expression on the NK cells and CD8 + T cells of CRC patients was increased significantly after 4 weeks of cetuximab therapy. Furthermore, cetuximab Studies have demonstrated that downregulation of expression of activating cells and upregulation of expression of inhibitory cells occur in the early stages of CRC [15] . The low functionality of NK cells could prevent NK cells from attacking and eliminating tumor cells in the circulation at early and advanced stages of the disease. Also, an immune system characterized by dysregulated NK cells could be a fertile environment for tumor establishment. Cetuximab improves the overall survival of patients with metastatic CRC, which demonstrates the efficacy of cetuximab if used as monotherapy in patients with metastatic CRC. We speculated that cetuximab might regulate the immune state of CRC patients, and our study confirmed this speculation. We found that cetuximab exerted its anti-CRC effect through regulation of the immune state, particularly the function of NK cells and CD8 + T cells. NK cells are considered to be the most effective anti-tumor lymphocytes [31] . NK cells have been applied for the treatment of patients with advanced CRC refractory to standard treatment, and such treatment was effective and safe [32, 33] . Besides, activated NK cells can kill tumor cells directly through perforin and granzymes or by inducing ADCC activity [34] . Furthermore, NK cells can produce cytokines such as IFN-γ, tumor necrosis factor-α (TNF-α) and IL-6 to enhance the antitumor effects and FasL/Fas-mediated apoptosis of tumor cells [16, 35] . CD137 is a member of the TNFR family, which is expressed on activated T cells, NKTlike cells and NK cells [36, 37] . Pre-clinical studies have revealed the antitumor properties of anti-CD137 monoclonal antibodies: they can enhance the activation and survival of tumorspecific CD8 + T cells, and increase the function of NK cells and DCs [38, 39] . In the present study, the number of NK cells was increased significantly after cetuximab treatment, and expression of CD137 and CD107a on the NK cells of CRC patients was increased significantly after 4 weeks of cetuximab therapy. An in vitro experiment suggested that PBMCs and NK cells can promote the apoptosis of K562 cells. We also found that cetuximab treatment could promote the cytotoxic acivity of PBMCs and NK cells against tumor cells.
Cetuximab has been approved as first-line treatment of EGFR-positive metastatic CRC and as remedial treatment for other chemotherapy-failed CRC patients [40, 41] . One study showed that cetuximab treatment increased the percentage of NK cells dramatically in vitro [42] . Subsequently, NK cells could lyse tumor cells through ADCC activity [43] . Studies have also shown that cetuximab promotes the toxicity of NK cells against tumor cells in vitro [44] . CD137 expression on CD4 + T cells and NK cells is also increased significantly after cetuximab therapy in mice [38] . In the present study, cetuximab increased the percentage of CD137 on NK cells and CD8 + T cells, but had no significant impact on the CD137 expression of CD4 + T cells. This phenomenon might have been because cetuximab therapy could induce expansion of the number of T cells in CRC patients.
However, after cetuximab treatment, changes in lymphocyte subsets in vivo have not been investigated, so we conducted these studies. Consistent with a previous study, cetuximab treatment increased the number of CD3 + T, CD8 + T and NK cells of CRC patients. Levels of CD137 and CD107a on NK cells and CD8 + T cells were increased markedly after cetuximab therapy. Also, the percentage of NKT-like cells was not changed significantly after cetuximab treatment. Treg cells often have immunosuppressive roles in tumors, and we found that cetuximab treatment reduced the percentage of Treg cells in the peripheral blood of CRC patients gradually. We inferred that cetuximab may inhibit the immunosuppressive effect of Tregs, thereby promoting the ability of immune cells to kill tumor cells.
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